EPISODE 095
The Stanford Biodesign program created another promising start-up in Zenflow. Co-founder and CEO Nick Damiano explains how the program’s fellows identified the opportunity in BPH and found the right tech to excite investors. Zenflow drew some early capital from unusual sources before embarking on an exhausting pursuit of the right Series A syndicate. Damiano shares some advice for other capital-hungry start-ups.
Overview: Great to see a monster Medtech Series A!
Surprises: Zenflow is working out of some offices with great karma.
Regrets: None. I’m feeling good about this one. I could have asked about the broader team.
Podcast Guest
Nick Damiano
Co-Founder & CEO
ZENFLOW
Nick Damiano is an experienced healthcare entrepreneur who started his career as an engineer before co-founding and leading several startup companies. He is currently Co-Founder & CEO of Zenflow, a clinical-stage medical device company developing an office-based therapy for BPH (enlarged prostate). Nick co-founded Zenflow along with Shreya Mehta out of the Stanford Biodesign fellowship in 2014. From 2013-14, he spent a year as the Lucile Packard Fellow in the Biodesign program. Nick was also Co-Founder & CTO of Nurep, a digital health company developing a mobile platform for remote surgical support that is currently in commercial use with leading medical device companies. Before Nurep, he worked in R&D engineering roles for several medtech startups and earned his MS/BS in Management Science & Engineering from Stanford University.
Meet Our Host
Geoff Pardo
Geoff has been in medtech for over two decades in both operational and investment roles. He is passionate about the industry potential and sharing stories from the front lines of innovation.